Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Marla Guzman"'
Autor:
Reshmi Morris MD, Aparna Prasad MD, Joseph Asaro MD, Marla Guzman MD, Leslie Sanders MD, Amanda Hauck MD, Gautam K. Singh MD, Philip T. Levy MD
Publikováno v:
Global Pediatric Health, Vol 4 (2017)
Background . Cardiovascular complications contribute to the high morbidity and mortality rate among children with anorexia nervosa (AN). Advances in cardiac imaging permit a more comprehensive assessment of myocardial performance in children that cou
Externí odkaz:
https://doaj.org/article/eeeed6e8e05949e19385758fa0753248
Autor:
Marla Guzman, Joyce S Hui-Yuen
Publikováno v:
Drug Design, Development and Therapy. 14:2503-2513
Belimumab (Benlysta®) is a fully humanized monoclonal antibody that inhibits B lymphocyte stimulator (BLyS, also known as B cell-activating factor of the tumor necrosis factor family) and was approved by the US Food and Drug Administration (FDA) and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8a83e1b46f09c8cb3d575f8e0982d7df
https://doi.org/10.2147/dddt.s216193
https://doi.org/10.2147/dddt.s216193
Autor:
Marla Guzman, Aparna Prasad, Amanda Hauck, Joseph Asaro, Reshmi Morris, Philip T. Levy, Leslie Sanders, Gautam K. Singh
Publikováno v:
Global Pediatric Health, Vol 4 (2017)
Global Pediatric Health
Global Pediatric Health
Background. Cardiovascular complications contribute to the high morbidity and mortality rate among children with anorexia nervosa (AN). Advances in cardiac imaging permit a more comprehensive assessment of myocardial performance in children that coul
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::33c902ca0a66d3e06f29d88b9e13228e
https://doi.org/10.1177/2333794x17727423
https://doi.org/10.1177/2333794x17727423
Publikováno v:
Journal of Adolescent Health. 58:S12
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::99feb6af83dbf99d67156791141bd73e
https://doi.org/10.1016/j.jadohealth.2015.10.039
https://doi.org/10.1016/j.jadohealth.2015.10.039
Publikováno v:
Journal of Clinical Neurology (Seoul, Korea)
The development of prevention therapies for Alzheimer's disease (AD) would greatly benefit from biomarkers that are sensitive to the subtle brain changes that occur in the preclinical stage of the disease. Reductions in the cerebral metabolic rate of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::324195d5a994f514d8c36bd779443639
https://doi.org/10.3988/jcn.2009.5.4.153
https://doi.org/10.3988/jcn.2009.5.4.153